Evan A. Stein
LIB Therapeutics LLC (United States) · 285 works · 31,228 citations · h-index 70
Top works
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels
- Estrogen plus Progestin and the Risk of Coronary Heart Disease
- THE RELATION OF DIET, CIGARETTE SMOKING, AND ALCOHOL CONSUMPTION TO PLASMA BETA-CAROTENE AND ALPHA-TOCOPHEROL LEVELS
- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
- Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
- Implementation of the women's health initiative study design
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
- Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
- Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia
- Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia
- The Efficacy of Intensive Dietary Therapy Alone or Combined with Lovastatin in Outpatients with Hypercholesterolemia
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients
- Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- Comparison of One-Year Efficacy and Safety of Atorvastatin Versus Lovastatin in Primary Hypercholesterolemia
- Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels